Approximately 40% of patients with muscle-invasive bladder cancer achieve a clinical complete response after neoadjuvant ...
Theralase® Technologies Inc. (TSXV: TLT) (OTCQB: TLTFF) ("Theralase®" or the "Company"), a clinical stage pharmaceutical ...
SurvivorNet on MSN
Diagnosing muscle-invasive bladder cancer: The initial work-up
When a doctor suspects bladder cancer, they will order a series of tests which may include urine tests (urinalysis or urine ...
MedPage Today on MSN
Organ-Sparing Strategy 'Promising' in Muscle-Invasive Bladder Cancer
Phase II study tested combination of sacituzumab govitecan plus pembrolizumab ...
SurvivorNet on MSN
A breakthrough for muscle-invasive bladder cancer: Padcev plus Keytruda drug combo could ...
Nearly 200,000 Americans are living with muscle-invasive bladder cancer (MIBC)—and after decades with few major advances, newly presented data may signal a turning point in how the disease is treated.
The 2026 GU ASCO annual meeting featured a renal cell carcinoma session and a discussant presentation by Dr. Beckermann, discussing three abstracts, “Belzutifan + lenvatinib versus cabozantinib for ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果